AUTHORS
Carly Harro, PhD, Hanna Sas-Nowosielska, PhD2, Gregory Donahue, PhD3, Sean Callahan, PhD4, Ebony Smith5, Abhisha Sawant Dessai, PhD6, Francisca deLuna Vitorino, PhD7, Renee Dean8, Ruofan Yu, PhD9, Benjamin A Garcia, PhD10, Regina Young, PhD11, Shelley L Berger, PhD12, Carl H. June Jr, MD13
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
8 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Despite the success of CD19 CAR T-cell therapies in many B-cell malignancies, response rates in chronic lymphocytic leukemia (CLL) remain limited. T-cell dysfunction has been reported in CLL patient apheresis products (Fraietta et al., Nature Medicine, 2018); however, many studies have focused on advanced disease and heavily pre-treated patients. The epigenetic and chromatin mechanisms underlying disease-associated T-cell dysfunction in treatment-naive early-stage CLL remain poorly characterized. We aim to understand this dysfunction to leverage targetable mechanisms to improve CLL CD19 CAR T cell response.
To address this gap, we performed integrated functional, transcriptomic, chromatin accessibility, histone proteomic, and imaging analyses of T cells from treatment-naive CLL patients and age-matched healthy donor controls to define the epigenetic features associated with CLL T-cell dysfunction. T cells were isolated from peripheral blood mononuclear cells of treatment-naive early-stage CLL patients and age-matched healthy donor (HD) controls. T-cell proliferative capacity was assessed following CD3/CD28 stimulation. Transcriptomic and chromatin accessibility profiling were performed using bulk RNA-seq and ATAC-seq, respectively. Histones were acid extracted for bottom-up mass spectrometry, and CUT&RUN was performed to evaluate selected targets identified through histone proteomic analysis. Nuclear architecture and chromatin compaction were assessed by DNA staining and quantitative image analysis. CD19 CAR T cells were generated from selected CLL and HD donors and evaluated in chronic stimulation assays to assess proliferation, persistence, and killing capacity.
Approximately 50% of treatment-naive early-stage CLL patients exhibited impaired proliferation capacity after CD3/CD28 stimulation, whereas the remaining CLL cohort maintained proliferation capacity comparable to HD controls. To further assess the functional phenotype, CD19 CAR T cells were generated from CLL T cells from dysfunctional CLL patients and HD controls. Dysfunctional CLL-derived CAR T cells displayed reduced expansion, CAR persistence, and killing capacity during chronic stimulation assays. To further characterize this cohort, we performed integrated transcriptomic and chromatin accessibility profiling. Dysfunctional CLL T cells demonstrated profound differences in transcriptomic and chromatin landscape compared to HD controls, consistent with reduced gene activation and increased chromatin repression. Pathway and gene set enrichment analysis identified reduced TCR signaling and genes involving nuclear organization and integrity, including components of the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. To identify transcriptional regulators, footprinting analysis was performed. Dysfunctional CLL T cells demonstrated reduced accessibility of AP-1 family transcription factor motifs, accompanied by decreased expression of activation-associated target genes and structural nuclear programs. To investigate the epigenetic mechanisms underlying CLL T cell chromatin remodeling, histone proteomic analysis was performed. Dysfunctional CLL T cells demonstrated loss of multiple activating histone modifications, including H3K4me1, H3K23ac, and H3K27me1, together with enrichment of repressive chromatin-associated marks such as H3K9me2/3. These changes were accompanied by reduced expression of activating chromatin regulators and enrichment of repressive chromatin-modifying programs. In contrast, proliferating CLL T cells retained a distinct chromatin state characterized by enrichment of H3K36 methylation despite loss of activation-associated marks. Additionally, consistent with transcriptomic, chromatin accessibility, and histone proteomic findings, quantitative imaging analysis demonstrated increased chromatin compaction and heterochromatin organization in dysfunctional CLL T cells compared with HD controls.
Taken together, these data demonstrate that treatment-naive CLL patients exhibit heterogeneous T-cell functional states. Dysfunctional CLL T cells are characterized by nuclear remodeling, loss of activation programs, and shift towards repressive chromatin states. These findings suggest that epigenetic remodeling occurs early in CLL and may contribute to reduced CAR T cell therapy fitness.
DISCLOSURES
Carly Harro, PhD: No relevant conflicts of interest to declare.